CAR-T therapy targeting BCMA for hard-to-treat myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This early-phase study tests a lab-made immune treatment (BCMA-targeted CAR-T cells) for people with relapsed or refractory multiple myeloma who have limited options. It may help your body recognize and attack myeloma cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that is BCMA-positive and has come back or not responded to treatment
- You are likely to live more than 12 weeks
- Your age is between 30 and 75
- You can give informed consent and agree to take part
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies CAR-T cells (a type of immune therapy) that target CS1 in people with multiple myeloma that has come back after earlier BCMA CAR-T. It may help control the cancer when previous CAR-T therapy or other treatments were not enough.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
This trial tests a one-time BCMA CAR-T cell treatment for people with multiple myeloma that relapsed or did not respond well to prior treatments. It may help by training your own immune cells to recognize and attack myeloma cells.
This early-phase study tests a CAR-T cell treatment made to target BCMA and TACI proteins in multiple myeloma. It may help people whose myeloma has come back or did not respond to prior treatments, especially after certain prior therapies.
This early trial tests a new CAR-T cell treatment targeting three proteins (CD19, CD22, and BCMA) on myeloma cells. It's for people whose myeloma came back or didn't respond to at least three prior treatments.
This trial tests a universal CAR-T cell therapy (made from donated cells) for multiple myeloma that has come back after at least two prior treatments. It may be an option if your cancer cells have a specific marker called BCMA and you have not had certain prior therapies.
Hear when a new Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.